Trial Profile
A Randomized, Open-label, Single-dose, 6-Period, 8-Sequence Crossover Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Subjects Under Fasted and Semi-fasted Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Seltorexant (Primary)
- Indications Insomnia; Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 08 Aug 2018 Status changed from recruiting to completed.
- 22 Feb 2018 New trial record